In October 2018, Resinco Capital acquired 49% of UK based pharma company ReFormation Pharmaceuticals in an all stock deal with the option to exercise future warrants. Rescino is a global investment company looking to expand into the cannabis/pharma sector.
The growth of the marijuana industry has been very rapid in the last two years. Since 2016, marijuana has been legalized in over 29 states. Support for marijuana legislation in the U.S. is also at its highest ever according to the latest Gallup poll.
Tilray, a Canadian pharmaceutical and cannabis company, made its debut on the NASDAQ this summer and soared from around $20 to as high as $300. Medical marijuana company Canopy Growth went from under $25 in August to over $52 in September, more than doubling.
Traders were celebrating the fact that the maker of Corona beer decided to invest a whopping $4 billion into the company. If that isn't confidence in the future of the marijuana industry, then what is?
Pot stocks may have experienced a healthy pullback recently after Canada legalized recreational marijuana on October 17th, but the gains have still been incredible this year and what could still be expected may blow these gains out of the water. Grand View Research has predicted that the global legal marijuana market is expected to reach a staggering $146.4 billion by end of 2025.
Resinco Capital Partners Inc. (OTC: $RSCZF) (CSE: RIN), has been developing a new concept: that the body's own stem cells that induce repair of tissues can be made to function more efficiently. This is very exciting and is something that could really shake up the medical arena.
Over the years, research after research has shown that marijuana is beneficial in the treatment of many conditions which include cancer, multiple sclerosis, epilepsy, arthritis, anxiety, IBS, and PTSD.
Epidiolex, the very first FDA-approved cannabis-based drug just became available in the U.S. at the start of November. When it gained FDA approval this past summer, it was a validation that the world is now ready for cannabinoid medicine.
The world could be more than ready for what Resinco Capital Partners Inc. (OTC: RSCZF) (CSE: RIN), is bringing to the table...
